On September 27, 2021, Marinus Pharmaceuticals, Inc. pursuant to its option under its previously disclosed Credit Agreement and Guaranty dated as of May 11, 2021 with Oaktree Fund Administration, LLC, as the Administrative Agent, and the lenders party thereto consummated a drawdown of $30.0 million of tranche A-2 term loans from the Credit Agreement As previously disclosed, the Credit Agreement provides for up to a $125.0 million term loan facility, $15.0 million of which was borrowed on the Closing Date. The Tranche A-2 Term Loan became available for the Company to utilize upon the written acceptance by the U.S. Food and Drug Administration of a New Drug Application filing elating to the use of ganaxolone in treatment of seizures associated with CDKL5 deficiency disorder The Tranche A-2 Term Loan is scheduled to mature on May 11, 2026, unless earlier prepaid. Pursuant to the Credit Agreement, and subject to the Company’s receipt of FDA approval of the CDD NDA and the achievement of certain financing, product development and product revenue milestones, and satisfaction of certain other conditions specified in the Credit Agreement, the Company would have the right to draw down three additional tranches in amounts up to $30.0 million, $25.0 million and $25.0 million, respectively. The Company intends to use the proceeds of the Tranche A-2 Term Loan to continue clinical development activities and commercialization efforts for ganaxolone and for other working capital and general corporate purposes.